How pancreatic tumors thwart an iron-driven demise

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy. Given that more than 95% of pancreatic ductal adenocarcinomas (PDACs) harbor such mutations, one might expect these tumors to be similarly vulnerable. Yet, in keeping with PDAC's notorious intractability, its tumors show no such vulnerability. Why this is so has been something of a mystery.